Luteinizing Hormone-Releasing Hormone Antagonist

Luteinizing Hormone-Releasing Hormone Antagonist (CPC catalog code LHRH-021) is a synthetic endocrine research peptide in the endocrine category. It is provided as a lyophilized ~1 mg vial for in-vitro research use only.

Published and internal research programs use Luteinizing Hormone-Releasing Hormone Antagonist as a reference standard in endocrine workflows — for example, receptor-binding and functional selectivity studies and second-messenger (camp / ip₁) profiling. Human clinical evidence is not established.

No. Luteinizing Hormone-Releasing Hormone Antagonist is a research-grade reference peptide and is not approved by the FDA or any national regulator for human or veterinary therapeutic use. It is offered exclusively for in-vitro laboratory research and does not ship to the United States for consumer use.

In a endocrine workflow, Luteinizing Hormone-Releasing Hormone Antagonist is reconstituted in sterile buffer or DMSO (solubility-dependent) and applied in the researcher's chosen assay format. HTRF cAMP, calcium mobilization (FLIPR), and radioligand binding are the standard readouts.

Store lyophilized at −20 °C, protected from light. Reconstitute in sterile 0.1% BSA/PBS. Follow your institution's standard operating procedures for handling synthetic peptides.

This kindr reference page mirrors CPC Scientific's catalog metadata for LHRH-021. The upstream reference sheet — including sequence, purity, MW, and application notes where published — is linked from the buy panel. All orders placed on kindr Peptides ship internationally under research-use terms only.

Research-grade peptides in the CPC catalog are synthesized by solid-phase peptide synthesis (SPPS), purified by preparative RP-HPLC, and characterized by analytical HPLC and mass spectrometry. Typical purity is ≥95%; certificate of analysis is available on request.